NCI-2021-04132

Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)

The MYTHIC study is a Phase 1 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-6306 in patients with advanced solid tumors. RP-6306 is an investigational drug being studied to assess its safety profile, how it is processed in the body (pharmacokinetics), its effects on the body (pharmacodynamics), and its potential clinical benefits in treating advanced solid tumors

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

pharmacodynamics: Study of how a drug affects the body, how is works, its effects, and how it interacts with its target

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04855656

Clinical Trial Site: Columbia

To see all available clinical trials click here.